Results 161 to 170 of about 22,142 (188)
Some of the next articles are maybe not open access.
2014
Abnormal B-cell receptor (BCR) signaling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signaling. Ibrutinib (PCI-32765) is a novel agent which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Mark-Alexander, Schwarzbich +1 more
openaire +2 more sources
Abnormal B-cell receptor (BCR) signaling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signaling. Ibrutinib (PCI-32765) is a novel agent which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Mark-Alexander, Schwarzbich +1 more
openaire +2 more sources
Management of adverse effects/toxicity of ibrutinib
Critical Reviews in Oncology/Hematology, 2019 PubMedID: 30878129Bruton tyrosine kinase signaling (BTK) is critical step for B-cell development and immunoglobulin synthesis. Ibrutinib is an orally bioavailable bruton tyrosine kinase inhibitor (BTKi) and forms an irreversible covalent bound to BTK at ...
Semra Paydaş
exaly +2 more sources
Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical
Drug Design, Development and Therapy, 2022Biqin Tan, Xiaokang Zeng, Youyou Yan
exaly